Cullinan Therapeutics (CGEM) Cash from Investing Activities (2020 - 2026)

Cullinan Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $32.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 11.93% year-over-year to $32.4 million in Q1 2026; TTM through Mar 2026 was $175.6 million, a 256.14% increase from a year earlier, with the FY2025 full-year figure at $180.0 million, up 232.04% from the prior year.
• Cash from Investing Activities improved to $32.4 million in Q1 2026 per CGEM's latest filing, from $22.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $300.9 million in Q2 2022 and bottomed at -$185.1 million in Q2 2024.
• The 5-year median for Cash from Investing Activities is $19.9 million (2024), against an average of $21.2 million.
• Across the five-year window, Cash from Investing Activities jumped 294.61% in 2022 and slumped 1628.59% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$28.6 million in 2022, then soared by 279.9% to $51.5 million in 2023, then slumped by 68.98% to $16.0 million in 2024, then jumped by 40.26% to $22.4 million in 2025, then surged by 44.76% to $32.4 million in 2026.
• Per Business Quant, the three latest CGEM Cash from Investing Activities figures stand at $32.4 million (Q1 2026), $22.4 million (Q4 2025), and $67.4 million (Q3 2025).